FDA Inspection
U.S. Continental Marketing, Inc.U.S. Continental Marketing, Inc. – FDA Inspection, Oct 30, 2018
Record Details
This FDA Inspection record concerns U.S. Continental Marketing, Inc., with an inspection on October 30, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 5e865a6b-c9f0-4293-b6a6-9a95b169e544
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1070430
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
- Enforcement
- Warning Letter
FDA Citations
6- 21 CFR 211.196Distribution Record Requirements
- 21 CFR 211.25(a)Training--operations, GMPs, written procedures
- 21 CFR 211.67(c)Cleaning/maintenance records not kept
- 21 CFR 211.125(a)Strict control not exercised over labeling issued
- 21 CFR 211.188(b)(7)Actual yield, % of theoretical yield
- 21 CFR 211.80(a)Written Procedures Not Followed
Full citation text and observation details available on the Dashboard.
Other FDA inspections of U.S. Continental Marketing, Inc.
1| Date | Classification | Office | Project area |
|---|---|---|---|
| July 21, 2022 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for U.S. Continental Marketing, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.